KRASG12C inhibitor‐derived PROTAC LC2 degraded KRASG12C in many cell lines of NSCLC to target the prevalent KRASG12C mutation in NSCLC; however, in comparison to the corresponding inhibitor MRTX844, to obtain the same level of Perk inhibition, a medication concentration that was 5 times higher was needed. The gene discussed is EIF2AK3; the disease is non-small cell lung carcinoma.